Education
About Us
Working with TipRanks
Follow Us
PBPH - ETF AI Analysis
Top Page
Portfolio Building Block World Pharma and Biotech Index ETF (PBPH)
Rating:70Neutral
Price Target:―
Positive Factors
Strong Top Holdings
Several of the largest positions, like Eli Lilly and Johnson & Johnson, are well-established companies that have shown strong performance in the healthcare sector.
Low Expense Ratio
The ETF charges a very low expense ratio, making it a cost-effective choice for investors.
Global Exposure
The fund includes companies from multiple countries, such as Switzerland, the UK, and Japan, providing some geographic diversification.
Negative Factors
Sector Concentration
With over 93% of its holdings in the healthcare sector, the ETF is highly exposed to risks specific to this industry.
High Concentration in Top Holdings
The top three holdings make up a significant portion of the portfolio, increasing reliance on their performance.
Modest Recent Performance
The ETF's recent returns have been positive but relatively modest, which may not appeal to investors seeking higher growth.
PBPH vs. SPDR S&P 500 ETF (SPY)
AUM518.52M
RegionDeveloped Markets
Expense Ratio0.13%
Beta0.83
IssuerPortfolio Building Block
Inception DateNov 24, 2025
Dividend Yield0.09%
Asset ClassEquity
Index TrackedBITA Global Pharma and Biotech Select Index - Benchmark TR Net
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume840,021
30 Day Avg. Volume480,987
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
29.05Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering51
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PBPH Summary
The Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) is an investment fund that focuses on healthcare companies, particularly in the pharmaceutical and biotechnology industries. It tracks the BITA Global Pharma and Biotech Select Index, which includes global leaders like Eli Lilly and Johnson & Johnson. This ETF is a great option for investors looking to benefit from the growth and innovation in healthcare, such as new drug developments and medical breakthroughs. However, since it focuses heavily on healthcare, its performance may be impacted if this sector faces challenges, like regulatory changes or slower innovation.
How much will it cost me?The Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) has an expense ratio of 0.13%, meaning you’ll pay $1.30 per year for every $1,000 invested. This is lower than average because it is a passively managed fund that tracks an index, which typically keeps costs down.
What would affect this ETF?The PBPH ETF could benefit from increased global healthcare spending, advancements in biotechnology, and demand for innovative treatments, especially as its top holdings include leading pharmaceutical companies like Eli Lilly and Johnson & Johnson. However, it may face challenges from regulatory changes, patent expirations, or economic downturns that could reduce healthcare budgets and impact the performance of its holdings. Additionally, its focus on developed markets may limit exposure to growth opportunities in emerging economies.
PBPH Top 10 Holdings
This ETF is a pure play on big pharma and biotech, with performance largely steered by a handful of global heavyweights. Eli Lilly is a bit of a mixed bag, recently losing some steam despite its outsized role in the portfolio. In contrast, Johnson & Johnson, Novartis, Roche, Merck, and Amgen have been rising and together form a powerful engine for the fund, helped by steady showings from names like Pfizer and Gilead. Geographically, it’s a developed-markets story, blending U.S. giants with European pharma leaders.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 13.92% | $73.65M | $934.24B | 13.89% | 72 Outperform | |
| Johnson & Johnson | 9.65% | $51.02M | $579.34B | 44.22% | 78 Outperform | |
| AbbVie | 6.81% | $36.05M | $406.87B | 7.38% | 66 Neutral | |
| Novartis AG | 5.38% | $28.48M | CHF234.59B | 22.14% | 80 Outperform | |
| Roche Holding AG | 5.28% | $27.93M | CHF272.90B | 26.73% | 73 Outperform | |
| Merck & Company | 5.05% | $26.70M | $286.28B | 22.33% | 80 Outperform | |
| AstraZeneca | 4.88% | $25.81M | $298.83B | 20.11% | 80 Outperform | |
| Amgen | 4.67% | $24.68M | $199.20B | 13.75% | 77 Outperform | |
| Gilead Sciences | 4.20% | $22.23M | $178.68B | 22.59% | 78 Outperform | |
| Pfizer | 3.44% | $18.21M | $153.81B | 1.20% | 74 Outperform |
PBPH Technical Analysis
Negative
―
Price Trends
26.21
Negative
Market Momentum
0.01
Positive
39.91
Neutral
22.21
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PBPH, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 26.84, equal to the 50-day MA of 26.21, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 0.01 indicates Positive momentum. The RSI at 39.91 is Neutral, neither overbought nor oversold. The STOCH value of 22.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PBPH.
PBPH Peer Comparison
Comparison Results
Performance Comparison
PBPH
Portfolio Building Block World Pharma and Biotech Index ETF
25.90
0.65
2.57%
PBOG
Portfolio Building Block Integrated Oil and Gas and Exploration and Production Index ETF
―
―
―
SRVR
Pacer Benchmark Data & Infrastructure Real Estate SCTR ETF
―
―
―
FINX
Global X Fintech Etf
―
―
―
SNSR
Global X Internet of Things ETF
―
―
―
GPZ
VanEck Alternative Asset Manager ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents